NasdaqCM - Delayed Quote USD

Regencell Bioscience Holdings Limited (RGC)

5.35 -0.30 (-5.31%)
At close: April 25 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Yat-Gai Au Founder, Chairman & CEO -- -- 1973
Ms. Michelle Chan Financial Controller -- -- --
Mr. Wai Hong Chung COO & Chief Strategy Officer 245.64k -- 1977
Dr. Yi-Chung Chao Ph.D. Special Advisor & Director 249.74k -- 1964
Mr. Tien Hsiang Chau Executive Officer 123.61k -- 1970
Ms. Antonia Assang Senior Vice President of Project Management -- -- --
Mr. Yat-Pui Au Chief Business Officer -- -- 1974

Regencell Bioscience Holdings Limited

Chinachem Leighton Plaza
9th Floor 29 Leighton Road
Causeway Bay
Hong Kong
852 2155 0823 https://www.regencellbioscience.com
Sector: 
Healthcare
Full Time Employees: 
12

Description

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Corporate Governance

Regencell Bioscience Holdings Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Related Tickers